Warfarin and heparin monitoring in antiphospholipid syndrome
Authors:
- 6 December 2024
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2024 (1) , 192-199
Abstract
Anticoagulation is central to the management of antiphospholipid syndrome (APS), an acquired thrombo-inflammatory disorder characterized by thrombosis (venous, arterial, or microvascular) or pregnancy morbidity, in association with persistent antiphospholipid antibodies (aPL; ie, 1 or more of lupus anticoagulant [LA], anticardiolipin, anti-beta-2- glycoprotein I, IgG, or IgM antibodies). The mainstay of anticoagulation in patients with thrombotic APS is warfarin or an alternative vitamin K antagonist (VKA) and, in certain situations, low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). Accurate assessment of anticoagulation intensity underpins optimal anticoagulant dosing for thrombus treatment or primary/secondary prevention. In patients with APS on warfarin, the international normalized ratio (INR) may not be representative of anticoagulation intensity due to an interaction between LA and the thromboplastin reagent used in the INR determination. In this review, we summarize the use of warfarin/VKA in patients with APS, along with venous and point-of-care INR monitoring. We also discuss the role and monitoring of LMWH/UFH, including in the anticoagulant refractory setting and during pregnancy.Keywords
This publication has 52 references indexed in Scilit:
- Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trialResearch and Practice in Thrombosis and Haemostasis, 2024
- The 2023 ACR/EULAR Antiphospholipid Syndrome Classification CriteriaArthritis & Rheumatology, 2023
- Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid SyndromesJACC, 2022
- 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal DiseasesArthritis & Rheumatology, 2020
- The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines ∗ —Anticoagulation During Cardiopulmonary BypassThe Annals of Thoracic Surgery, 2018
- Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS RegistryAutoimmunity Reviews, 2016
- Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-AnalysisJournal of General Internal Medicine, 2016
- A systematic review and meta‐analysis of the epidemiology and burden of venous thromboembolism among pregnant womenInternational Journal of Gynecology & Obstetrics, 2015
- Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndromeAnnals of Hematology, 2015
- Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndromeInternational Journal of Gynecology & Obstetrics, 2011